One phase IIb clinical trial administered Setmelanotide to participants with obesity with heterozygous MC4R deficiency and obese controls over 28 days, observing a placebo-adjusted weight loss of 2.6 kg and 4.0 kg respectively [74]. The gene discussed is MC4R; the disease is obesity disorder.